Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression

Frontiers in Public Health - Tập 8
Zhiliang Hu1,2, Yanling Lv3, Chuanjun Xu4, Wenkui Sun5, Wei Chen6, Zhihang Peng7, Chen Chen2, Xiang Cui7, Damin Jiao2, Cong Cheng2, Yün Chi2, Hongxia Wei2, Xia Zhang8, Yi Zeng8, Zhang Xia1,8, Yongxiang Yi2
1Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
2Nanjing Infectious Disease Center, the Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
3Department of Respiratory Medicine, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
4Department of Radiology, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
5Department of Respiratory & Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
6Department of Clinical Research Center, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
7School of Public Health, Nanjing Medical University, Nanjing, China
8Department of Tuberculosis, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China

Tóm tắt

Từ khóa


Tài liệu tham khảo

Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet., 395, 497, 10.1016/S0140-6736(20)30183-5

Gorbalenya, 2020, The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat Microbiol., 5, 536, 10.1038/s41564-020-0695-z

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med., 382, 727, 10.1056/NEJMoa2001017

Hu, 2020, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, Sci China Life Sci., 63, 706, 10.1007/s11427-020-1661-4

Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med., 8, 475, 10.1016/S2213-2600(20)30079-5

Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet., 395, 1054, 10.1016/S0140-6736(20)30566-3

Situation Report-1412020

Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med., 382, 1787, 10.1056/NEJMoa2001282

Li, 2020, Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial, Med., 10.1016/j.medj.2020.04.001

Mehra, 2020, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet, 10.1016/S0140-6736(20)31180-6

Beigel, 2020, Remdesivir for the treatment of Covid-19 — preliminary report, N Engl J Med, 10.1056/NEJMoa2007764

Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet., 395, 1569, 10.1016/S0140-6736(20)31022-9

Goldman, 2020, Remdesivir for 5 or 10 days in patients with severe Covid-19, N Engl J Med., 10.1056/NEJMoa2015301

Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet., 395, 473, 10.1016/S0140-6736(20)30317-2

Shang, 2020, On the use of corticosteroids for 2019-nCoV pneumonia, Lancet., 395, 683, 10.1016/S0140-6736(20)30361-5

Chen, 2006, Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience, Chest., 129, 1441, 10.1378/chest.129.6.1441

Pan, 2020, Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia, Radiology., 295, 715, 10.1148/radiol.2020200370

Van Der Wal, 2011, ipw: an R Package for inverse probability Weighting, J Statist Software, 43, 1, 10.18637/jss.v043.i13

Conti, 2020, Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies, J Biol Regul Homeost Agents., 34, 1, 10.23812/CONTI-E

Coperchini, 2020, The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system, Cytokine Growth Factor Rev., 53, 25, 10.1016/j.cytogfr.2020.05.003

Xiong, 2020, Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients, Emerg Microbes Infect., 9, 761, 10.1080/22221751.2020.1747363

Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med., 8, 420, 10.1016/S2213-2600(20)30076-X

Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet., 395, 1033, 10.1016/S0140-6736(20)30628-0

Zhang, 2020, The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the Perspectives of clinical immunologists from China, Clin Immunol., 214, 108393, 10.1016/j.clim.2020.108393

Ritchie, 2020, Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?, Lancet., 395, 1111, 10.1016/S0140-6736(20)30691-7

Lee, 2004, Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients, J Clin Virol., 31, 304, 10.1016/j.jcv.2004.07.006

Arabi, 2018, Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome, Am J Respir Crit Care Med., 197, 757, 10.1164/rccm.201706-1172OC

Thông tin
Thông tin xuất bản

Frontiers in Public Health

Tập 8

Thông tin tác giả